ストックスクリーナーアプリを入手
16.99
3.53%
0.58
前日終値:
$16.41
開ける：
$16.64
24時間の取引高:
257.24K
Relative Volume:
0.41
時価総額：
$912.01M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-50.75%
1か月 パフォーマンス:
-55.49%
6か月 パフォーマンス:
+61.96%
1年 パフォーマンス:
+83.08%
1日の値動き範囲:
$16.23
$17.36
1週間の範囲:
$13.50
$17.50
52週間の値動き範囲:
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.99 | 880.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
798.27 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.81 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
796.96 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
337.42 | 35.45B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
Why Zenas BioPharma Inc. stock is favored by top institutionsJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - PR Newswire
What insider trading reveals about Zenas BioPharma Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
Will Zenas BioPharma Inc. stock benefit from upcoming earnings reportsWeekly Investment Recap & Safe Investment Capital Preservation Plans - ulpravda.ru
Will Zenas BioPharma Inc. stock reach Wall Street targetsRisk Management & Reliable Momentum Entry Alerts - ulpravda.ru
Is Zenas BioPharma Inc. stock a bargain at current levels2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Yahoo Finance UK
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study - sharewise.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas ... - Bluefield Daily Telegraph
Morgan Stanley Downgrades Zenas BioPharma (ZBIO) Rating and Pric - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% Following Analyst Downgrade - MarketBeat
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Canada
Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win - Yahoo Finance
Jefferies lowers Zenas Biopharma stock price target to $48 on trial data - Investing.com Canada
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions? - Yahoo Finance
Zenas BioPharma Stock Pre-Market (-4.0%) : Fallout From Phase 3 Data Disappointment - Trefis
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial, ETPharma - ETPharma.com
Zenas BioPharma’s immune disorder drug meets main goal in late-stage trial - whbl.com
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio - Sahm
Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results - Investing.com Canada
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Investor's Business Daily
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Equal Weight" Rating by Morgan Stanley - MarketBeat
Zenas BioPharma Stock Plummets 57% Despite Positive Phase 3 INDIGO Results - Nasdaq
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap DownHere's Why - MarketBeat
Obexelimab’s Strong Phase 3 Data and Differentiated Positioning Underpin Zenas BioPharma Buy Rating and $44 Target - TipRanks
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
Zenas BioPharma Shares Phase III INDIGO Win as Obexelimab Cuts IgG4-RD Flare Risk 56% - MarketBeat
Zenas BioPharma announces positive phase 3 Obexelimab results - MSN
Indigo grills: Street querying Zenas phase III IgG4-RD beat - BioWorld MedTech
Zenas shares crash after top drug misses expectations in immune disease study - BioPharma Dive
Zenas shares plunge on weaker-than-expected data for immune disorder drug - marketscreener.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Zenas posts late-stage trial data for lead asset (ZBIO:NASDAQ) - Seeking Alpha
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - TradingView — Track All Markets
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results - TipRanks
Zenas BioPharma stock falls after Phase 3 trial results By Investing.com - Investing.com Canada
Zenas BioPharma’s obexelimab shows 56% reduction in IgG4-RD flares By Investing.com - Investing.com Canada
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - The Manila Times
Experimental IgG4-related disease drug sharply cuts flare risk in trial - Stock Titan
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A Promising 34.95% Upside in the Biotech Arena - DirectorsTalk Interviews
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus - ts2.tech
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus - ts2.tech
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.4%Here's Why - MarketBeat
Zenas Biopharma Inc (ZBIO) 財務データ
Zenas Biopharma Inc (ZBIO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Zenas Biopharma Inc (ZBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
| MOULDER LEON O JR | See Remarks |
Oct 07 '25 |
Buy |
20.85 |
36,928 |
769,949 |
36,928 |
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
0.92%
大文字化:
|
ボリューム (24 時間):